Protagonist Therapeutics Inc
NASDAQ:PTGX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.79
48.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
Change in Deffered Taxes
Protagonist Therapeutics Inc
Change in Deffered Taxes Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Deffered Taxes | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
Change in Deffered Taxes
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Change in Deffered Taxes
-$2.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Change in Deffered Taxes
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Change in Deffered Taxes
-$1.5B
|
CAGR 3-Years
-93%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Change in Deffered Taxes
-$531.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
18%
|
CAGR 10-Years
-13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Change in Deffered Taxes
-$763.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-30%
|
|
Protagonist Therapeutics Inc
Glance View
Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.
You don't have any saved screeners yet
